Connecticut Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Connecticut Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$82.4K	Buy	+86,249	New	+$95.4K	﹤0.01%	338

Other funds holding LCTX

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return

Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return

Chapin Davis Baltimore, Maryland $520M AUM 117.57% 1-Year Est. Return

Founders Capital Management (Texas) Houston, Texas $220M AUM 46.36% 1-Year Est. Return

Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return

ELCO Management New York $213M AUM 25.23% 1-Year Est. Return

Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return

GAMMA Investing

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Connecticut Wealth Management's LCTX Position: Q3 2026 in Review

Connecticut Wealth Management opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 86,249 shares worth $82.4K. The stake represents ﹤0.01% of the portfolio and ranks #338 among its holdings.

11 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

Connecticut Wealth Management held 86,249 shares of Lineage Cell Therapeutics worth $82.4K as of Q3 2026.
Lineage Cell Therapeutics was a new Connecticut Wealth Management position in Q3 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Connecticut Wealth Management's portfolio in Q3 2026, its #338 holding.
11 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Connecticut Wealth Management's 13F filing for Q3 2026, filed 13 Oct 2026.